New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter second-line sequencing.
Linda Y. Wu, MD
Advertisement
Articles by Linda Y. Wu, MD
Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and smarter therapy pairings to extend responses in trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5